Myrtelle Announces Encouraging Interim Results from Phase 1/2 Gene Therapy Trial for Canavan Disease

Myrtelle Inc. announced encouraging interim results from its Phase 1/2 clinical trial of rAAV-Olig001-ASPA (MYR-101), an investigational gene therapy ...

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeKnolsightsContact UsPricing
One Research Court, Suite 450, Rockville, MD 20850
info@pienomial.com
+91 9876543210
© 2025 Pienomial. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/KnloSights/Clinical Trial Updates/Myrtelle Announces Encouraging Interim Results from Phase 1/2 Gene Therapy Trial for Canavan Disease